The effects of implementing virtual reality headsets during transarterial treatment of malignant liver tumors

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00030195

Enrollment

Registered

2024-02-28

Start date

2024-07-22

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C22.0 C22.0

Interventions

Group 1: TACE (Transarterial chemoembolization) with VR headset Group 2: TACE without VR headset

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - clinically indicated transarterial chemoembolization of the liver - signed study consent form

Exclusion criteria

Exclusion criteria: - Contraindication for clinically indicated transarterial chemoembolization chemoembolization -Patient age under 18 years - Migraine with aura - claustrophobia - Epilepsy - Severe balance disorder - Kinetosis - Acute psychosis

Design outcomes

Primary

Measure	Time frame
1. State-Trait Anxiety Inventory - Trait Version (STAI- T) and State Version (STAI-S)	—

Secondary

Measure	Time frame
2. Likert scale to assess the sensation of pain 3. diagnosis of the occurrence of postembolic syndrome during the hospital stay 4. vital signs 5. simulator sickness questionnaire (not in the control group without VR headset) 6. ingroup presence questionnaire (not in the control group without VR headset) 7. examination time, fluoroscopy time, radiation dose 8. survey of the physicians performing the treatment with regard to patient communication during the procedure	—

Measure

Time frame

2. Likert scale to assess the sensation of pain 3. diagnosis of the occurrence of postembolic syndrome during the hospital stay 4. vital signs 5. simulator sickness questionnaire (not in the control group without VR headset) 6. ingroup presence questionnaire (not in the control group without VR headset) 7. examination time, fluoroscopy time, radiation dose 8. survey of the physicians performing the treatment with regard to patient communication during the procedure

—

Countries

Germany

Contacts

Public ContactCharlotte Wintergerst

Uniklinik Freiburg im Breisgau

charlotte.kulka@uniklinik-freiburg.de+49 761 270 39540

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026